News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Clovis Oncology (CLVS) Announces CO-1686 Clinical Data Accepted As Oral Presentation At 2014 European Lung Cancer Conference


12/23/2013 6:29:09 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

ovis Oncology (NASDAQ:CLVS) announced today that an abstract discussing the findings of the ongoing Phase I portion of the Phase I/II clinical study of CO-1686 has been accepted for Proffered Paper (Oral) presentation during the 4th European Lung Cancer Conference (ELCC). CO-1686 is the Company’s novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. The conference takes place March 26-29, 2014 in Geneva, Switzerland.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES